Abstract
A 56-year-old woman with ankylosing spondylitis, treated for 3 months with infliximab, developed miliary tuberculosis with mediastinal lymphadenopathies and brain and splenic lesions. After initial improvement under anti-tuberculous therapy, she suffered an unexpectedly prolonged paradoxical worsening with several episodes of lymphadenopathy, including life-threatening ones, over a period of more than 14 months of follow-up. The outcome was favorable as a result of corticosteroid and surgical treatments. This phenomenon reflects a paradoxical reaction precipitated by infliximab withdrawal.
Copyright © 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
MeSH terms
-
Adrenal Cortex Hormones / therapeutic use
-
Antibodies, Monoclonal / adverse effects*
-
Antitubercular Agents / adverse effects
-
Antitubercular Agents / therapeutic use
-
Female
-
Humans
-
Infliximab
-
Lymphatic Diseases / etiology
-
Lymphatic Diseases / surgery
-
Lymphatic Diseases / therapy
-
Mediastinal Diseases / etiology
-
Mediastinal Diseases / therapy
-
Middle Aged
-
Opportunistic Infections / etiology
-
Opportunistic Infections / therapy
-
Recurrence
-
Spondylitis, Ankylosing / therapy*
-
Tuberculosis, Miliary / etiology*
-
Tuberculosis, Miliary / therapy*
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Adrenal Cortex Hormones
-
Antibodies, Monoclonal
-
Antitubercular Agents
-
Tumor Necrosis Factor-alpha
-
Infliximab